Literature DB >> 19046572

Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy.

C Florian Bentzinger1, Klaas Romanino, Dimitri Cloëtta, Shuo Lin, Joseph B Mascarenhas, Filippo Oliveri, Jinyu Xia, Emilio Casanova, Céline F Costa, Marijke Brink, Francesco Zorzato, Michael N Hall, Markus A Rüegg.   

Abstract

Mammalian target of rapamycin (mTOR) is a central controller of cell growth. mTOR assembles into two distinct multiprotein complexes called mTOR complex 1 (mTORC1) and mTORC2. Here we show that the mTORC1 component raptor is critical for muscle function and prolonged survival. In contrast, muscles lacking the mTORC2 component rictor are indistinguishable from wild-type controls. Raptor-deficient muscles become progressively dystrophic, are impaired in their oxidative capacity, and contain increased glycogen stores, but they express structural components indicative of oxidative muscle fibers. Biochemical analysis indicates that these changes are probably due to loss of activation of direct downstream targets of mTORC1, downregulation of genes involved in mitochondrial biogenesis, including PGC1alpha, and hyperactivation of PKB/Akt. Finally, we show that activation of PKB/Akt does not require mTORC2. Together, these results demonstrate that muscle mTORC1 has an unexpected role in the regulation of the metabolic properties and that its function is essential for life.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19046572     DOI: 10.1016/j.cmet.2008.10.002

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  315 in total

1.  Alpha-lipoic acid supplementation reduces mTORC1 signaling in skeletal muscle from high fat fed, obese Zucker rats.

Authors:  Zhuyun Li; Cory M Dungan; Bradley Carrier; Todd C Rideout; David L Williamson
Journal:  Lipids       Date:  2014-11-01       Impact factor: 1.880

2.  Myopathy caused by mammalian target of rapamycin complex 1 (mTORC1) inactivation is not reversed by restoring mitochondrial function.

Authors:  Klaas Romanino; Laetitia Mazelin; Verena Albert; Agnès Conjard-Duplany; Shuo Lin; C Florian Bentzinger; Christoph Handschin; Pere Puigserver; Francesco Zorzato; Laurent Schaeffer; Yann-Gaël Gangloff; Markus A Rüegg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

Review 3.  Feedback on fat: p62-mTORC1-autophagy connections.

Authors:  Jorge Moscat; Maria T Diaz-Meco
Journal:  Cell       Date:  2011-11-11       Impact factor: 41.582

Review 4.  Building muscle: molecular regulation of myogenesis.

Authors:  C Florian Bentzinger; Yu Xin Wang; Michael A Rudnicki
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-02-01       Impact factor: 10.005

Review 5.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

Review 6.  The muscle fiber type-fiber size paradox: hypertrophy or oxidative metabolism?

Authors:  T van Wessel; A de Haan; W J van der Laarse; R T Jaspers
Journal:  Eur J Appl Physiol       Date:  2010-07-03       Impact factor: 3.078

7.  mTORC1 links protein quality and quantity control by sensing chaperone availability.

Authors:  Shu-Bing Qian; Xingqian Zhang; Jun Sun; Jack R Bennink; Jonathan W Yewdell; Cam Patterson
Journal:  J Biol Chem       Date:  2010-07-06       Impact factor: 5.157

8.  Pten loss induces autocrine FGF signaling to promote skin tumorigenesis.

Authors:  Kristina Hertzler-Schaefer; Grinu Mathew; Ally-Khan Somani; Sunil Tholpady; Madhavi P Kadakia; Yiping Chen; Dan F Spandau; Xin Zhang
Journal:  Cell Rep       Date:  2014-02-27       Impact factor: 9.423

Review 9.  Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms.

Authors:  Shaodong Guo
Journal:  J Endocrinol       Date:  2014-01-08       Impact factor: 4.286

10.  mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.

Authors:  David R Driscoll; Saadia A Karim; Makoto Sano; David M Gay; Wright Jacob; Jun Yu; Yusuke Mizukami; Aarthi Gopinathan; Duncan I Jodrell; T R Jeffry Evans; Nabeel Bardeesy; Michael N Hall; Brian J Quattrochi; David S Klimstra; Simon T Barry; Owen J Sansom; Brian C Lewis; Jennifer P Morton
Journal:  Cancer Res       Date:  2016-10-06       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.